|
Graves Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We applied HLA imputation to genome-wide association study (GWAS) data for Graves' disease in Japanese (n = 9,003) and found that amino acid polymorphisms of multiple class I and class II HLA genes independently contribute to disease risk (HLA-DPB1, HLA-A, HLA-B and HLA-DRB1; P < 2.3 × 10(-6)), with the strongest impact at HLA-DPB1 (P = 1.6 × 10(-42)).
|
26029868 |
2015 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a direct comparison between GD and HT, we identified GD-specific susceptible class II molecules, HLA-DP5 (HLA-DPB1*05:01; Pc = 1.0 × 10(-9)) and HLA-DR14 (HLA-DRB*14:03; Pc = .0018).
|
24285682 |
2014 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-DPB1*05:01 is the major gene of GD in our population and singly accounts for 48.4% of population-attributable risk.
|
21307958 |
2011 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Stratification analyses suggested a possible synergistic interaction of CTLA4 with HLA-A 02 and -DPB1 0501 in the susceptibility to TBII-positive GD.
|
20300120 |
2010 |
|
Graves Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These two patient groups were associated with similar HLA-A alleles and different HLA-DPB1 alleles, suggesting the presence of two genetic factors for GD within the HLA region; one is HLA-A linked and may be related to thyroid organ specificity, the other is HLA-DP linked and may control the severity of autoimmunity.
|
16698425 |
2006 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-DPB1*0501 was increased (92.9% vs. 54.3%, P < 0.05, RR: 11.0, chi 2:6.57) in the patients with Graves' disease.
|
7781492 |
1995 |
|
Graves Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Namely, the HLA-DP allele (DPB1*0501) and the HLA-B allele (B46) are primarily involved in the pathogenesis of early-onset and late-onset Graves' disease in Japanese, respectively.
|
8026987 |
1994 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the co-occurrence of HLA-B8 with DPB1*0402 was significantly commoner in patients with GD (p < 0.021, RR = 6.2) and EOMG (p < 0.0007, RR = 10.8) than in controls, although the HLA-DPB1*0402 by itself showed no significant increase.
|
8061167 |
1994 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-DR17/DQ2 was found to be more commonly associated with HLA-DPB1*0101 on the Affected haplotypes (from family members affected with Graves' disease) while associated with DPB1*0401 on the Ab + ve haplotypes (deduced from thyroid autoantibody positive unaffected members).
|
8088306 |
1994 |
|
Graves Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This observation suggests a synergic involvement of a HLA class II allele (DPB1*0501) and an HLA class I allele (HLA-A2) in the pathogenesis of Graves' disease.
|
1363421 |
1992 |
|
Graves Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that HLA-DPB 2.1/8 may confer a protective effect in Graves' disease with respect to ophthalmopathy.
|
2401099 |
1990 |
|
Graves Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HLA-DP, DQ and DR gene expression in Graves' disease and normal thyroid epithelium.
|
3120348 |
1987 |